This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
6 Citations 15 Q&As
Facts about Runt-related transcription factor 2.
CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1(I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive component (OCFRE) (By similarity).
Human | |
---|---|
Gene Name: | RUNX2 |
Uniprot: | Q13950 |
Entrez: | 860 |
Belongs to: |
---|
No superfamily |
Acute myeloid leukemia 3 protein; AML3CCD; CBFA1; CBFA1MGC120022; Core-binding factor subunit alpha-1; MGC120023; PEA2-alpha A; PEBP2A; PEBP2A1CCD1; PEBP2aA1; PEBP2-alpha A; runt domain, alpha subunit 1; runt-related transcription factor 2; RUNX2; SL3/AKV core-binding factor alpha A subunit; SL3-3 enhancer factor 1 alpha A subunit
Mass (kDA):
56.648 kDA
Human | |
---|---|
Location: | 6p21.1 |
Sequence: | 6; NC_000006.12 (45328317..45551082) |
Specifically expressed in osteoblasts.
Nucleus.
If you're looking for a low-cost RUNX2 marker that is reliable, Boster Bio may be the solution. Boster has antibodies that have been validated across multiple platforms and with known positive and negative samples. The company also uses known negative samples to confirm the antibody's high affinity and specificity. Boster also offers early reviewers product credits. Scientists from all over the world could benefit from Boster's research by this method.
The rapid in vitro testing of hRUNX2-luc transcriptional activity is in good agreement with an assay of functional late-stage for bone development , called mineralization. On the contrary, the activity of hRUNX2 correlates poorly with the activity of the common functional marker of osteogenesis that is early in its development, ALP. However, this marker could be used to determine the effects of osteogenic compounds on bone formation.
The inhibitor of CADD522 blocks RUNX2 binding to the MMP13 promoters in a time and dose-dependent way. The compound also increases RUNX2 levels within MCF7 cells and RUNX2-KD cells, but has no or little impact on MCF7-Empty. However, RUNX2 ectopic expression increases CBF-b levels, both in MCF7 cells and T47D cells.
Recent research has shown that the expression of Runx1 and Runx2 differ in bone marrow cells as well as non-hematopoietic tissues. Additionally, the relative expression of mRNAs for Runx1 and Runx2 were discovered to be highly related in osteoblasts, endothelial cells and non-endothelial cell. In the same study, Runx1 and Runx2 were expressed at significantly higher levels than other types of non-hematopoietic cell populations.
The ELISA for cancer treatment which targets RUNX2 has numerous advantages. In comparison to other cancer treatments it doesn't have adverse side effects as a result of chemotherapy. It also has an excellent therapeutic index. RUNX2 is not expressed in mature glandular tissues or in bone. By targeting RUNX2 can help stop BC growth or reverse the dependence on glycolysis in cancer cells.
IHC for the RUNX2 marker identifies osteoclast-like cells, which express RANKL. This marker has been implicated in the development of cleidocranial dysfunction syndrome, an autosomal dominant skeletal dysplasia. However the exact diagnosis is still difficult to come up with. This study examined RUNX2 expression in the aortic roots using mice as a model for Cleidocranial Dysplasia.
RUNX2 can be found in a wide range of cancers which includes liver and pancreatic cancer. In cell research, knocking down RUNX2 results in a decrease of the biological behavior that is malignant. It is not known what function RUNX2 is playing in the fight against cancer, but it is believed that it promotes non-small-cell lung cancer development via EMT-related pathways. Although this remains unclear more research is required.
In a previous study, we identified a binding site for RUNX2 in the CXCR4 promoter. This region is known as bp -1046 to -1032. EMSA confirmed this binding site by marking the DNA of SGC7901 cells with CGGAGTGGTTGGACC. If we used anti-RUNX2 to act as an indicator, we saw a supershifting band in Figure 5C. This supershift band was not detected by Control IgG.
The immunoreactivity scores for the RUNX2 marker are calculated by multiplying the intensity of staining. The scoring scale is divided into four categories: 0 represents no staining, 1 indicates that there is no staining; 2 is a positive-looking cell. Similarly, IRS > 4 indicates a positive cell. The K-M survival curves show that a shorter life span for the mouse.
Boster Bio RUNX2 is a universal primer compatible with many gene expression systems. It was first developed to identify osteoblast-related genes. The RUNX2 gene is located in a variety of different tissues, including bone. RT-qPCR is a method that can be used with this marker to determine the expression levels of this protein within various tissues.
Extracting RNA from periodontal tissue was carried out. Two milligrams of total RNA were isolated for each group. The iScript(tm) and CDNA synthesis kits reverse-transcribed the transcript into cDNA. The samples were run through an polyacrylamide gel at 8%, and then transferred to membranes made of nitrocellulose. After incubation at 95°C for 15 minutes, the membranes were rinsed with PBS. Then, secondary and primary antibodies were added to the samples.
Boster Bio RUNX2 is an osteoblast marker for humans which has numerous advantages over other methods. Its ability to detect osteoblasts is unrivaled. Its high degree of specificity allows researchers to study and quantify the osteoblast's expression in human tissues. In fact, a high concentration of this gene is more specific than ever before. Boster Bio RUNX2 marker is able to detect osteoblastic differentiation in hPDLSCs. This is the hallmark of periodontal disorders.
qPCR employing the RUNX2 gene marker is able to detect the expression level of the C-myc-tagged transcription. The Runx2 gene exhibits high expression in osteosarcoma, egg rooster rat and rooster embryos. C/OSE2 was identified as the binding site in previous studies. The results of this study proved that three motifs have the capability of competing with Runx2 for the c-myc-DNA target. The most upstream motif, Cyp3, competed with Runx2 while the two other motifs, TLE1 and Cyp2, did not.
Runx2 is a transcriptional molecule that induces osteocalcin RNA expression is essential for Cyp11a1 expression. Ascorbic acid and b-glycerophosphate are used to induce osteoblast differentiation. Ad-Runx2 cells infected by the virus were tested for RNA and compared to levels from control. The samples were collected at 4-day intervals and analyzed as described in A.
The RNA of cells infected with the Runx2 gene was isolated using an established protocol and Takara easy-dilution kit. The RNA was then hybridized with cDNA arrays, Mouse Genome 430 2.0 Array. The statistical analysis of these results revealed that Runx2 is involved in the coordinated control of sterol metabolism. Its target genes are regulated by the gene. The cells that are infected with Runx2 are believed to express Cyp11a1 which is 32 kDa protein.
Osteoblast growth is controlled by the activation of Wnt/b-catenin signals. Cyp11a1 expression is controlled by Runx2, and its expression is a rate-limiting factor of Cyp11a1 in osteoblasts. In contrast, the expression of Runx2 in non-osseous cells is elevated proportionally to the activation of the RUNX2 gene.
We utilized VSMCs from ex vivo to explore the role of Runx2 in the cell cycle. The cells were cultured until they reached 70% confluence. Following that we triedpsinized them, then resuspended the cells in 0.6 percent low melting point agarose. The cells were placed on ice for 20 minutes in darkness. The cells were then incubated on ice for 20 mins in darkness. Following that, the cells were transferred to a PVDF membrane where they were probed with antibodies against Myc and OSX.
To determine if Runx2 promoter-mediated DNA damage leads to cell death, we employed a threshold measure method, that measures the relative expression levels of the Runx2 gene in different samples. The relative expression levels of Runx2 were calculated using a 2-Ct method that measures folds of mRNA. The results were reported in folds of mRNA, and the proportions were calculated from each sample.
Runx2 expression is associated with the extent of cancer in patients suffering from advanced stage. The gene is implicated in various types of cancer, such as pancreatic, thyroid, and lung tumors. It has been linked to poor prognosis. In cancer cell lines, expression of Runx2 is associated with a low survival and is highly predictive of progression of cancer. But more studies are needed to confirm the validity of Runx2 gene expression.
Boster Bio: Best Uses of the Runx2 Marker is a useful tool for researchers looking to identify the role of RUNX2 within a particular biological process. Its distinctive features include the ability to identify the RUNX2 gene in a variety of biological samples, such as cells and tissues. This marker is especially useful for studies in the area of cell metabolism and regeneration. The expression of RUNX2 is higher in oMSCs and hMSCs and the results were comparable across time intervals.
It is important that you keep in mind that human cells are able to produce hundreds of thousands of cell surface antigens. Thus, there are many different techniques for detecting RUNX2 in a variety of tissues, including immunohistochemistry. One way to detect this marker is by using fluorochrome-conjugated antibodies. These antibodies can be used in flow cytometry to eliminate the possibility of non-specific binding. This could cause problems with other tests for immunoassays. Another technique that uses fluorescent secondary antibodies is direct immunofluorescence staining which involves incubating cells with an antibody that is directly linked to the fluorophore. This method reduces the risk of non-specific binding resulting from large complexes of antibodies and fluorophore. Moreover, secondary antibodies may not be able to enter cells.
The RUNX2 gene is a key transcription factor that regulates the differentiation of osteoblasts. Additionally, it is expressed in similar amounts in both hMSCs and oMSCs during osteogenic differentiation. This gene is also linked to ALPL and COL1A1.
PMID: 9182765 by Mundlos S., et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia.
PMID: 9434946 by Geoffroy V., et al. Genomic organization, expression of the human CBFA1 gene, and evidence for an alternative splicing event affecting protein function.
*More publications can be found for each product on its corresponding product page